Low-stakes 2018 deal with Regeneron leads to bump for Kiniksa on pericarditis readout

Pivotal data for rilonacept in recurrent pericarditis put Kiniksa on track to bring its first program to market and gain rights from Regeneron to additional indications.

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) shares rose $2.97 (13%) to $26 Monday, adding $173.9 million to the company's market cap, on the readout from the Phase III RHAPSODY trial of rilonacept...